trending Market Intelligence /marketintelligence/en/news-insights/trending/vvqjwo8xl0rb2s_utdrvmg2 content esgSubNav
In This List

BioMérieux H1 profit up 32.8% YOY


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

BioMérieux H1 profit up 32.8% YOY

BioMérieux SA said earnings for the six months ended June 30 grew 32.8% year over year, while sales increased 3.1%.

Net income of consolidated companies for the period reached €134 million, up from €101 million in 2017. EPS for the period increased to €1.14, from €0.86 in the previous year.

The S&P Capital IQ normalized EPS consensus estimate for first-half 2018 was €0.99.

The French in vitro diagnostics company attributed the growth to strong sales growth and an improvement in the product mix. BioMérieux said these, among other items, more than offset negative currency effects.

Sales climbed to about €1.17 billion in the first six months of 2018, from about €1.13 billion in the year-ago period.

For full-year 2018, BioMérieux expects contributive operating income of between €340 million and €350 million, and sales to grow by around 9.5%.